Intensive insulin therapy of newly diagnosed T2D could decrease the secretory demand and protect β-cell function, while sulfonylurea such as gliclazide may accelerate β-cell dysfunction through inducing insulin secretion and over stimulating β-cells. This evidence concerns the gene INS and type 2 diabetes mellitus.